Ubs Oconnor LLC Rapt Therapeutics, Inc. Transaction History

Ubs Oconnor LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$6.87 - $26.45 $76,937 - $296,213	11,199 Added 18.1%	73,088 $656,000
Q4 2023 Feb 14, 2024	SELL	$11.28 - $25.46 $360,136 - $812,861	-31,927 Reduced 34.03%	61,889 $1.54 Million
Q3 2023 Nov 14, 2023	SELL	$16.34 - $24.66 $49,020 - $73,980	-3,000 Reduced 3.1%	93,816 $1.56 Million
Q2 2023 Aug 14, 2023	BUY	$16.06 - $21.61 $1.55 Million - $2.09 Million	96,816 New	96,816 $1.81 Billion
Q1 2023 May 15, 2023	BUY	$17.19 - $30.8 $71,252 - $127,666	4,145 Added 4.72%	92,046 $1.69 Million
Q4 2022 Feb 14, 2023	BUY	$16.28 - $24.6 $294,488 - $444,989	18,089 Added 25.91%	87,901 $0
Q3 2022 Nov 14, 2022	SELL	$17.96 - $30.46 $160,526 - $272,251	-8,938 Reduced 11.35%	69,812 $1.68 Billion
Q2 2022 Aug 12, 2022	BUY	$10.26 - $23.59 $705,375 - $1.62 Million	68,750 Added 687.5%	78,750 $1.44 Million
Q1 2020 May 15, 2020	BUY	$11.86 - $48.86 $118,600 - $488,600	10,000 New	10,000 $212,000

104

27.1M

26.7K

2.4K

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $24.9M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.